In medicine, a breakpoint is a concentration threshold used to decide whether a specific antibiotic can effectively treat a specific bacterium. When a lab tests bacteria from your infection against an antibiotic, the breakpoint is the dividing line that determines whether the result comes back as “susceptible” (the drug should work) or “resistant” (it probably won’t). These values shape which antibiotic your doctor prescribes, and they’re revised regularly as resistance patterns shift.
How Breakpoints Work in Practice
When you have a bacterial infection, the lab grows the bacteria from your sample and exposes them to antibiotics at different concentrations. The goal is to find the minimum inhibitory concentration, or MIC: the lowest amount of drug that stops the bacteria from growing. That MIC number, on its own, doesn’t tell your doctor much. It only becomes useful when compared against a fixed breakpoint.
If the MIC falls at or below the breakpoint for “susceptible,” the antibiotic is expected to clear the infection at normal doses. If it falls above the breakpoint for “resistant,” the drug will likely fail even at higher doses. There’s also a middle category. The European standard-setting body defines it as “susceptible, increased exposure,” meaning the antibiotic can still work but may need a higher dose, a longer infusion time, or is effective because the drug naturally concentrates at the infection site (like a urinary tract infection where the drug accumulates in urine).
One important nuance: MIC testing has a built-in margin of error of about one dilution step in either direction. An MIC of 2 mg/L could actually be 1 or 4 mg/L. When the MIC lands right at the breakpoint, this uncertainty matters. It could mean the difference between a “susceptible” and “resistant” reading, which is one reason clinicians sometimes look at the actual MIC number rather than just the category label.
Who Sets These Thresholds
Two organizations set breakpoints for most of the world. In the United States, the Clinical and Laboratory Standards Institute (CLSI) publishes annual breakpoint tables. In Europe, the European Committee on Antimicrobial Susceptibility Testing (EUCAST) does the same. The U.S. Food and Drug Administration also plays a role by formally recognizing CLSI breakpoints for use in drug labeling and by automated lab systems.
These two systems are not identical, and the differences have real consequences. EUCAST breakpoints tend to be more restrictive. In a study comparing results from the same bacterial samples interpreted under both systems, 19 out of 20 reviewed studies found that switching from CLSI to EUCAST criteria increased reported resistance rates. For one common drug combination tested against E. coli, resistance jumped from about 20% under CLSI rules to over 52% under EUCAST rules. The bacteria didn’t change. Only the threshold for calling them “resistant” did. This means the same infection in the same patient could be labeled differently depending on which country’s lab processed the sample.
What Goes Into Setting a Breakpoint
Breakpoints aren’t arbitrary cutoffs. They’re built from three pillars of evidence. The first is the natural range of MIC values seen in “wild-type” bacteria, meaning strains that haven’t developed any resistance mechanisms. This establishes a baseline called the epidemiological cutoff, which flags bacteria that have picked up resistance genes even if they might still respond to treatment. The clinical breakpoint for susceptibility is usually set higher than this cutoff, because some bacteria with low-level resistance can still be treated successfully.
The second pillar involves how the drug behaves in your body. Scientists look at how much of the antibiotic reaches the infection site, how long it stays above effective levels, and how it’s cleared. Three key relationships matter: how the drug’s peak concentration compares to the MIC, how the total drug exposure over 24 hours compares to the MIC, and what percentage of the day the drug concentration stays above the MIC. Different classes of antibiotics rely on different relationships. Some kill bacteria best with high peak concentrations, while others need to maintain steady levels throughout the day.
The third pillar is clinical outcome data from actual patients. If people treated with a given antibiotic start failing therapy when their infection’s MIC hits a certain level, that real-world evidence informs where the breakpoint should sit.
Why Breakpoints Change Over Time
Breakpoints are not permanent. They get revised when new evidence shows the old thresholds no longer predict treatment success. A clear example: before 2010, CLSI considered a common hospital antibiotic effective against a major group of gut bacteria at concentrations up to 4 µg/mL. Clinical data then showed that patients with infections at MICs between 2 and 4 µg/mL were doing poorly on treatment. The susceptible breakpoint was dropped to 1 µg/mL. Bacteria that would have been called treatable under the old standard were now flagged as resistant.
Several triggers can prompt a revision. New resistance mechanisms may emerge in bacteria that were previously susceptible. Updated studies may reveal that patients are failing therapy at drug levels previously considered adequate. Changes in standard dosing practices can also shift the math, since breakpoints assume a particular dose and schedule. As recently as January 2025, the FDA recognized revised breakpoints for several widely used antibiotics against common hospital pathogens, reflecting years of accumulated clinical evidence.
Epidemiological Cutoffs vs. Clinical Breakpoints
You may encounter the term “epidemiological cutoff value” (ECOFF) alongside breakpoints. These serve a different purpose. An ECOFF identifies bacteria that have acquired any resistance mechanism at all, even a subtle one. It draws the line between completely wild-type bacteria and those that have started down the path of resistance. Clinical breakpoints, by contrast, answer a more practical question: will this drug work in this patient at the recommended dose?
Because clinical breakpoints factor in drug levels achievable in the body and clinical outcome data, they’re often set higher than the ECOFF. A bacterium might have a low-level resistance mechanism that pushes its MIC above the ECOFF but still be classified as susceptible by clinical breakpoint standards, because the drug concentrations reached during normal dosing are high enough to overcome that resistance. ECOFFs are primarily useful for surveillance, helping public health authorities track resistance trends before they become clinically relevant.
How Lab Results Reach Your Doctor
Most hospital labs today use automated systems that test bacteria against panels of antibiotics and generate results in hours rather than days. These machines have breakpoint tables programmed into their software, so results are automatically categorized as S (susceptible), I (intermediate or increased exposure), or R (resistant). When breakpoints are updated by CLSI or EUCAST, the lab’s software needs to be updated too. This process can lag, particularly when older automated systems require FDA clearance before incorporating new breakpoints.
The result your doctor sees on the report is shaped entirely by whichever breakpoint table the lab uses. A pathogen listed as susceptible to a particular antibiotic at one hospital could theoretically be listed as resistant at another if one lab has updated its breakpoints and the other hasn’t. This is why infectious disease specialists sometimes request the raw MIC number rather than relying solely on the S/I/R category, especially for serious infections where the margin between success and failure is thin.